Hypogonadism Drug Market - Industry Trends t

Hypogonadism Drug Market - Industry Trends & Forecast to 2026 with key players like Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc.

Hypogonadism Drug Market By Type (Hypergonadotropic Hypogonadism and Hypogonadotropic Hypogonadism), Therapy Type (Testosterone Replacement Therapy and Steroid Replacement Therapy), Mechanism of Action Type (Steroidal Androgens &Gonadotropins), Route of Administration (Oral, Injectable, Tropical), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026

Market Analysis: Global Hypogonadism Drug Market

Global hypogonadism drug market is rising gradually with a substantial CAGR in the forecast period of 2021-2026. Growing number hypogonadism population and robust product pipeline are the key drivers for market growth.

Download full sample report of Hypogonadism Drug Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hypogonadism-drug-market

Market Definition: Global Hypogonadism Drug Market

Hypogonadism is a rare endocrine disorders characterized by insufficient production of testosterone hormone due to failure of testicles. This hormone is essential for functioning of sexual characteristics. The person with hypogonadism may experience weakness, loss of libido, infertility and osteoporosis.

According to the article published in Clarus Therapeutics, it was estimated that over 7.00 million testosterone replacement related drug prescriptions were prescribed by physician. Growing population of hypogonadism and robust pipeline for development of newer therapies are the key factors for market growth.

Market Drivers

Increase in prevalence rate of hypogonadism worldwide acts as a driver for the market

Increase in the rate of research and development initiatives is driving the market

Rising awareness about hypogonadism therapy and technological advancement is driving the market growth

Ongoing clinical trials is being carried out by many pharmaceuticals companies which acts as a driver for the market

Market Restraints

Effective treatment is either unavailable or unaffordable

Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrain the growth if the market

Inadequate knowledge about hypogonadism in some developing countries

Segmentation: Global Hypogonadism Drug Market ​​​​​​​

By Type

·        Hypergonadotropic Hypogonadism

·        Hypogonadotropic Hypogonadism

By Therapy Type

·        Testosterone Replacement Therapy

·        Steroid Replacement Therapy

By Treatment

·        Medication      

·        Hormone therapy

·        Surgery

By Mechanism of Action Type

·        Steroidal androgens

·        Testosterone

·        Methyltestosterone

·        Gonadotropins

·        Chorionic Gonadotropin

·        Follicle Stimulating Hormone

By Route of administration

·        Oral

·        Injectable

·        Topical

 By End Users

·        Hospitals

·        Homecare

·        Specialty Clinics

·        Others

By Geography

·        North America

·        U.S.

·        Canada

·        Mexico

·        South America

·        Brazil

·        Argentina

·        Rest of South America

·        Europe

·        Germany

·        France

·        United Kingdom

·        Italy

·        Spain

·        Russia

·        Turkey

·        Belgium

·        Netherlands

·        Switzerland

·        Rest of Europe

·        Asia-Pacific

·        Japan

·        China

·        South Korea

·        India

·        Australia

·        Singapore

·        Thailand

·        Malaysia

·        Indonesia

·        Philippines

·        Rest of Asia Pacific

·        Middle East & Africa

·        South Africa

Egypt

·        Saudi Arabia

·        United Arab Emirates

·        Israel

·        Rest of Middle East & Africa

Key Developments in the Market:

In March 2019, Clarus Therapeutics received the FDA approval for Jatenzo (testosterone undecanoate), an oral testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. This approval represents the first oral treatment option for hypogonadism in men.

In October 2018, Antares Pharma received the FDA approval for Xyosted (testosterone enanthate) Injection, a testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. The FDA approval of Xyosted expanded the company’s branded portfolio in therapeutic area of endocrinology.

Competitive Analysis:

Global hypogonadism drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global hypogonadism market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global hypogonadism drug market are AbbVie Inc., ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly and Company, Clarus Therapeutics, Endo Pharmaceuticals Inc, Merck & Co., Inc., Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc., Antares Pharma, Pfizer Inc., Aytu BioScience, Inc., Diurnal, HYUNDAIPHARM. Co Ltd., Perrigo Company plc, Bio-Techne and many others.

Get full details of TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hypogonadism-drug-market  

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-hypogonadism-drug-market  

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research 

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Browse Related Reports @

Monkeypox Market 

Acitretin Market